B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS

Detalles Bibliográficos
Autores principales: van de Donk, NWCJ, Delforge, M, Agha, M, Cohen, AD, Cohen, YC, Hillengass, J, Anguille, S, Kerre, T, Roeloffzen, W, Schecter, JM, De Braganca, KC, Varsos, H, Wang, L, Vogel, M, Zudaire, E, Corsale, C, Akram, M, Geng, D, Nesheiwat, T, Pacaud, L, Sonneveld, P, Zweegman, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Best Abstracts - Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012122/
http://dx.doi.org/10.1097/01.HS9.0000829568.10814.bc
_version_ 1784687735934550016
author van de Donk, NWCJ
Delforge, M
Agha, M
Cohen, AD
Cohen, YC
Hillengass, J
Anguille, S
Kerre, T
Roeloffzen, W
Schecter, JM
De Braganca, KC
Varsos, H
Wang, L
Vogel, M
Zudaire, E
Corsale, C
Akram, M
Geng, D
Nesheiwat, T
Pacaud, L
Sonneveld, P
Zweegman, S
author_facet van de Donk, NWCJ
Delforge, M
Agha, M
Cohen, AD
Cohen, YC
Hillengass, J
Anguille, S
Kerre, T
Roeloffzen, W
Schecter, JM
De Braganca, KC
Varsos, H
Wang, L
Vogel, M
Zudaire, E
Corsale, C
Akram, M
Geng, D
Nesheiwat, T
Pacaud, L
Sonneveld, P
Zweegman, S
author_sort van de Donk, NWCJ
collection PubMed
description
format Online
Article
Text
id pubmed-9012122
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-90121222022-04-18 B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS van de Donk, NWCJ Delforge, M Agha, M Cohen, AD Cohen, YC Hillengass, J Anguille, S Kerre, T Roeloffzen, W Schecter, JM De Braganca, KC Varsos, H Wang, L Vogel, M Zudaire, E Corsale, C Akram, M Geng, D Nesheiwat, T Pacaud, L Sonneveld, P Zweegman, S Hemasphere Best Abstracts - Oral Presentations Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9012122/ http://dx.doi.org/10.1097/01.HS9.0000829568.10814.bc Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Best Abstracts - Oral Presentations
van de Donk, NWCJ
Delforge, M
Agha, M
Cohen, AD
Cohen, YC
Hillengass, J
Anguille, S
Kerre, T
Roeloffzen, W
Schecter, JM
De Braganca, KC
Varsos, H
Wang, L
Vogel, M
Zudaire, E
Corsale, C
Akram, M
Geng, D
Nesheiwat, T
Pacaud, L
Sonneveld, P
Zweegman, S
B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
title B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
title_full B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
title_fullStr B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
title_full_unstemmed B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
title_short B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
title_sort b07: safety and efficacy of ciltacabtagene autoleucel, a chimeric antigen receptor t-cell therapy directed against b-cell maturation antigen in patients with multiple myeloma and early relapse after initial therapy: cartitude-2 results
topic Best Abstracts - Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012122/
http://dx.doi.org/10.1097/01.HS9.0000829568.10814.bc
work_keys_str_mv AT vandedonknwcj b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT delforgem b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT agham b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT cohenad b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT cohenyc b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT hillengassj b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT anguilles b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT kerret b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT roeloffzenw b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT schecterjm b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT debragancakc b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT varsosh b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT wangl b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT vogelm b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT zudairee b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT corsalec b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT akramm b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT gengd b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT nesheiwatt b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT pacaudl b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT sonneveldp b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results
AT zweegmans b07safetyandefficacyofciltacabtageneautoleucelachimericantigenreceptortcelltherapydirectedagainstbcellmaturationantigeninpatientswithmultiplemyelomaandearlyrelapseafterinitialtherapycartitude2results

Ejemplares similares